Vericiguat CAS No.:1350653-20-1

Introduction

Vericiguat is a novel medication that is used for the treatment of heart failure. It is a stimulator of soluble guanylate cyclase (sGC), an enzyme that plays a crucial role in the regulation of the cardiovascular system. Vericiguat is a highly selective sGC stimulator and has shown excellent therapeutic potential in the treatment of heart failure patients with reduced ejection fraction (HFrEF). Vericiguat is also known by the trade name ‘Verquvo’ and is exclusively manufactured by Merck, a leading pharmaceutical company.

Product Description

Vericiguat (CAS No.:1350653-20-1) is a highly effective medication that is used to treat heart failure patients with reduced ejection fraction. Vericiguat is available in tablet form and is administered orally. The active ingredient in Vericiguat is a selective sGC stimulator that works by enhancing the sensitivity of sGC to NO, leading to increased levels of cyclic guanosine monophosphate (cGMP). The increase in cGMP levels leads to vasodilation, reduces inflammation, inhibits collagen production, and overall improves cardiac function.

Vericiguat has been extensively studied in large random clinical trials (VICTORIA) and has shown to reduce the risk of heart failure hospitalization or cardiovascular death in patients with HFrEF. Vericiguat is approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and is the first medication that has shown significant clinical benefits in patients with HFrEF with a recent hospitalization.

Product features

Vericiguat is a highly selective sGC stimulator that works by enhancing the sensitivity of sGC to NO. The key features of Vericiguat include:

1. Highly Effective: Vericiguat has been extensively studied and has shown to effectively reduce the risk of heart failure hospitalization or cardiovascular death in patients with HFrEF.

2. Selective sGC Stimulator: Vericiguat is a highly selective sGC stimulator that works by enhancing the sensitivity of sGC to NO.

3. Approved by the US FDA and EMA: Vericiguat is approved by the US FDA and EMA for the treatment of heart failure patients with reduced ejection fraction.

4. Product Safety: Vericiguat has a good safety profile, and the adverse events are usually mild and dose-related.

5. Convenient Administration: Vericiguat is available in tablet form and is administered orally, making it convenient for patients to take the medication at home.

Target Market

Vericiguat is an advanced medication that is specifically designed to help patients with heart failure. The medication is suitable for:

1. Heart Failure Patients: Vericiguat is specifically designed to help patients with heart failure, especially those with reduced ejection fraction.

2. Patients with Recent Hospitalization: Vericiguat has shown clinical benefits in patients with HFrEF with a recent hospitalization.

3. Physicians and Cardiologists: Vericiguat is an advanced medication that is recommended by physicians and cardiologists for the treatment of heart failure patients with reduced ejection fraction.

Marketing Strategy

The marketing strategy for Vericiguat should take into consideration the following factors:

1. Product Benefits: The marketing campaign should emphasize the benefits of Vericiguat, including its high effectiveness and convenient administration.

2. Target Market: The target market for Vericiguat should be cardiologists and physicians who prescribe medications for heart failure patients.

3. Educational Materials: The marketing campaign should also include educational materials that explain the mechanism of action of Vericiguat, its clinical benefits, and the types of patients who would benefit from the medication.

4. Clinical Trials: The marketing campaign should highlight the results of the clinical trials that demonstrate the efficacy of Vericiguat in reducing the risk of heart failure hospitalization or cardiovascular death.

5. Brand Value: Finally, the marketing campaign should emphasize the brand value of Vericiguat, and how it is manufactured by a leading pharmaceutical company, Merck.

Conclusion

Vericiguat (CAS No.:1350653-20-1) is a highly effective medication that is used to treat heart failure patients with reduced ejection fraction. The medication is a selective sGC stimulator that works by enhancing the sensitivity of sGC to NO, leading to increased levels of cGMP. The increase in cGMP levels leads to vasodilation, reduces inflammation, inhibits collagen production, and overall improves cardiac function. Vericiguat is approved by the US FDA and EMA and is the first medication that has shown significant clinical benefits in patients with HFrEF with a recent hospitalization. The marketing strategy for Vericiguat should focus on the product benefits, target market, educational materials, clinical trials, and brand value.

Chemical Structure : Vericiguat

CAS No.: 1350653-20-1

 

Vericiguat(BAY 1021189)

Catalog No.: URK-V1425 Only Used For Lab.

Vericiguat (BAY 1021189) is a novel potent, selective, orally available soluble guanylate cyclase (sGC) stimulator (MEC=0.3 uM), stimulating sGC NO-independently and in synergy with NO.

Biological Activity

Vericiguat (BAY 1021189) is a novel potent, selective, orally available soluble guanylate cyclase (sGC) stimulator (MEC=0.3 uM), stimulating sGC NO-independently and in synergy with NO.
Vericiguat (BAY 1021189) inhibits the U46619-induced contractions of porcine coronary artery rings with IC50 of 956 nM.
Vericiguat (BAY 1021189) reduces the coronary perfusion pressure in rat heart Langendorff preparations with no effect on heart rate, left ventricular diastolic pressure, and contractility.

Physicochemical Properties

References

1. Follmann M, et al. J Med Chem. 2017 Jun 22;60(12):5146-5161.

URK-V1425_COA

URK-V1425_SDS

URK-V1425_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We have a team of highly skilled professionals dedicated to the production and sale of our Metabolic Enzyme/Protease Library products.
• We establish a talent growth mechanism with good service consciousness and excellent professional skills, self-motivation, self-restraint, self-management and self-development.
• We offer competitive pricing and flexible payment options for our Metabolic Enzyme/Protease Library products.
• We are committed to the industries and are constantly enhancing our business model in support of our core mission of highest quality Vericiguat CAS No.:1350653-20-1, lowest cost and shortest delivery time.
• As a supplier and manufacturer, we offer competitive prices for our products and services.
• Since establishment, we have been adhering to the business philosophy of 'professionalism, focus' and 'providing satisfactory service to customers', so that our products have been unanimously recognized in the industry.
• Our Metabolic Enzyme/Protease Library products are highly effective and efficient, providing excellent value for our customers.
• Our company produces and manages in strict accordance with modern enterprise management system, attaches great importance to product quality and service quality, and operates in strict accordance with quality management system.
• We offer a wide range of Metabolic Enzyme/Protease Library products to meet our customers' needs.
• The new development strategy we formulated is aimed at improving profitability and optimizing the corporate structure.

Hot Tags: vericiguat cas no.:1350653-20-1, China vericiguat cas no.:1350653-20-1, epigenetic library for epigenetic analysis of epigenetic mechanism research, inhibitors for viral infections, inhibitors for enzyme activity, epigenetic library for epigenetic regulation of cell invasion, epigenetic library for epigenetic regulation of cell signalling, epigenetic library for epigenetic modulation